PATENT CLAIM ANALYSIS

Application Number: 15939218
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["514", "428000"]

Abstract:
The disclosure provides methods for treating estrogen receptor positive (ER + ) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER +  cancers.

Claim (Index 21):
The method of  claim 20 , wherein the aromatase inhibitor is exemestane, letrozole, or anastrozole.

Metadata:
- Claim Count in Document: 65.0
- Percentile: 90.0
- Lexical Diversity: 1.28
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14645578', '14753397', '14717069', '15589391', '16475980']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7936492923121833
- 35 USC 102 Novelty (BERT): 0.5252453225852505
- Combined Prediction Score: 0.76680889533949
- Mean Citation Score: 320.457534
- Max Citation Score: 345.9269700000001
- Similarity Product: 249.0036747999717

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test